# KPV peptide FAQ: mechanism, safety, dosing, and legal status questions > KPV peptide FAQ: what it does, how it reduces inflammation, whether it is safe, its relationship to alpha-MSH, and its FDA 503A status. Direct, cited answers. Direct answers drawn from the published literature and the audited FDA record — what is known, what is preclinical, and what has no human answer yet. ## What does KPV peptide do? KPV is the C-terminal tripeptide (residues 11-13) of alpha-MSH that retains the parent hormone's anti-inflammatory activity while lacking its pigmentary action [4]. In research models it suppresses NF-kB and MAP-kinase signaling and reduces pro-inflammatory cytokine production [1], and the effect appears largely melanocortin-receptor-independent [2]. ## What is KPV peptide? KPV (Lys-Pro-Val) is a linear tripeptide corresponding to residues 11-13 of alpha-melanocyte-stimulating hormone, studied as a melanocortin-derived anti-inflammatory peptide [4]. Its formula is C16H30N4O4 and its molecular weight is 342.44 Da [1]. ## What is KPV? KPV stands for the tripeptide lysine-proline-valine, the C-terminal fragment of alpha-MSH studied for anti-inflammatory and gut/epithelial signaling [4]. It is not an independently circulating hormone. ## How does KPV reduce inflammation? In research models KPV dampens inflammation mainly by inhibiting NF-kB and MAP-kinase signaling and lowering pro-inflammatory cytokine secretion [1]; the effect appears largely melanocortin-receptor-independent and is retained in MC1R-deficient models [2]. ## How is KPV related to alpha-MSH? KPV is the C-terminal tripeptide (residues 11-13) of alpha-melanocyte-stimulating hormone; it preserves the parent hormone's anti-inflammatory activity but lacks its pigmentary (melanogenic) action [4]. ## Does KPV cause skin pigmentation or tanning like other melanocortins? KPV's defining feature in the literature is anti-inflammatory action without pigmentary effect; unlike melanocortin agonists used for tanning, the C-terminal KPV fragment lacks the melanogenic activity of full alpha-MSH [4]. ## What is PepT1 and why does it matter for KPV? PepT1 (SLC15A1) is an intestinal di/tripeptide transporter that carries KPV directly into epithelial cells; it is upregulated in inflamed gut tissue, which makes it a route to target KPV to the inflamed colon [1]. ## What is KPV peptide used for? In the published literature KPV is studied as an anti-inflammatory agent, most extensively in murine colitis/IBD models, and also in corneal and skin wound-repair and antimicrobial research; it has no approved human use [1][2][6][9]. ## What is KPV used for? In research, KPV is used as an anti-inflammatory probe and candidate, most heavily in gut/colitis models via PepT1-mediated uptake, with additional wound-healing, skin, and antimicrobial studies [1][6][9]. ## What is KPV peptide good for? Research interest centers on anti-inflammatory and gut/epithelial signaling — colitis models via PepT1 uptake — plus exploratory wound-healing and antimicrobial findings; all evidence is preclinical [1][6][9]. ## What are the benefits of KPV peptide? Reported research findings include reduced colonic inflammation in mouse colitis [2], accelerated corneal re-epithelialization in rabbits (8/8 by 60 hours) [6], and downregulated inflammatory signaling across cell types [1][8]; these are preclinical findings, not demonstrated human benefits. ## Is KPV peptide worth it? That is an evaluative question the literature cannot answer: KPV's evidence base is mechanistic and preclinical, with no human trials, so any value judgment for human use would outrun the data [1][16]. ## Can you take KPV and BPC-157 together? No controlled study has evaluated a KPV plus BPC-157 combination in humans; the research record contains no data on co-administration of these two peptides, so no research-based combination guidance exists. ## Is KPV peptide safe? No published human clinical trials of KPV exist, so human safety is unestablished; what is known comes from in vitro and animal studies [1][2]. It is a research chemical for laboratory use only [20]. ## Who should not take KPV peptide? KPV is not approved for human use and has no validated human dosing or safety data, so the literature does not define a human use population; it is sold by research suppliers for laboratory use only [16][20]. ## How long does it take KPV peptide to work? There is no human timeline; in animal models effects were measured over days — for example, complete corneal re-epithelialization by 60 hours in a rabbit study [6] — but these do not translate to a human onset time. ## How quickly does KPV peptide work? Onset is model-dependent in animal research and undefined in humans; as a peptidase-labile tripeptide, free KPV is expected to be rapidly degraded, which is why much research uses stabilizing formulations [1][5]. ## Can you take KPV every day? No human dosing schedule has been established. Research doses vary widely by model — for example, ~10 nM in vitro, ~100 uM in mouse drinking water, and multiple daily topical eye-drop doses in rabbits [1][6]. ## How often do I inject KPV peptide? Research administration in the literature is largely oral (drinking water, encapsulated nanoparticles) or topical, not injection [1][5][6]; no validated human injection frequency exists. ## How long should I take KPV peptide for? No human treatment duration is established. Animal studies ran over days to weeks depending on the model [1][6]; these durations are not human dosing recommendations. ## What is KPV peptide dosage? There is no established human dose. Reported research concentrations include ~10 nM in vitro, ~100 uM in mouse drinking water, and 1-10 mg/mL topical eye drops in rabbits [1][6]. ## What are KPV peptide side effects? No human side-effect profile has been published because there are no human trials; safety is characterized only in preclinical models, and KPV remains a research-only chemical [16][20]. ## Is KPV legal? KPV is not an FDA-approved drug and is sold as a research chemical for laboratory use only; it is not approved as a drug or dietary supplement in any major jurisdiction [16][20]. Under the FD&C Act it could be used in 503A compounding only if it were on FDA's 503A bulks list or otherwise eligible, and KPV is currently a candidate under PCAC evaluation rather than a listed substance [16][18]. This is general information, not legal advice. ## Can you get KPV from a compounding pharmacy? Legally compounded access requires an eligible ingredient plus a licensed-prescriber evaluation and a valid, patient-specific prescription routed through a 503A pharmacy or 503B outsourcing facility, with telehealth as a possible front-end consultation channel [19]. Because KPV is currently a candidate under FDA evaluation rather than a listed bulk substance, its eligibility for routine 503A compounding is exactly the open question the July 2026 PCAC meeting is scheduled to examine; no outcome should be assumed [16][18]. ## What is the FDA 503A status of KPV? KPV is a bulk drug substance "being considered for inclusion on the 503A Bulks List," individually named on the FDA Pharmacy Compounding Advisory Committee agenda for the meeting scheduled July 23-24, 2026, in both free base and acetate forms [18]. The audited FDA reference does not assign KPV a numbered 503A Category; its present-tense status is research peptide, not FDA-approved, scheduled for PCAC evaluation — a step in evaluation, not a final listing decision [16][18]. For the full picture, see [KPV legal status and 503A access](/legal-status). --- A blacklight-poster field guide to the KPV tripeptide — every colitis, mechanism, and corneal figure read straight off the published record and cited to source, the no-human-data and research-only lines glowing in plain sight; no clinic behind the poster and nothing here dispensed or sold.